Patent · US Active

Potent and selective inhibitors of hepatitis C virus

US9181227B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignees

COCRYSTAL PHARMA, INC. · US
EMORY UNIVERSITY · US

Inventors

Steven J. Coats · McDonough, US
Franck Amblard · Tucker, US
Hongwang Zhang · Tucker, US
Longhu Zhou · Atlanta, US
Richard Anthony Whitaker · Amarillo, US
Tamara Rosario McBrayer · Tucker, US
Raymond F. Schinazi · Decatur, US
Junxing Shi · Duluth, US

Key dates

Filing date	Aug 8, 2014
Grant date	Nov 10, 2015
Priority date	—
Expiry date	Aug 8, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.